Tuesday, July 29, 2014 6:03:39 AM
Might be some links on my board here to different technical trading sites, ie take a look at Japanese Candlesticking.
You brought up the 20dma, I'm thinking you meant to say 50dma. The major DMA's offer good support/resistance targets but keep in mind that you should look for confirmation unless you're using the 50/200dma's as your stop loss (remember your plan).
ISR's sell signal actually came through the end of June imo. Now, providing ISR doesn't tank, it is showing some potential buy signals but need confirmation. Watch the stochastic family, Fast sto, slow sto and full sto (which say watch/accumulate cautiously imo). I combine that with the divergence of the ADX which says wait imo. Then the other support levels come into play, 2.50 was a good level to see hold. stockta.com posts some decent support resistance levels.
A lot of different ways to look at the puzzle, just need to see which angle is right for you.
My own opinion. I'm not a paid promoter or analyst/advisor.
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent CATX News
- Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- Perspective Therapeutics to Participate in Upcoming Investor Conferences in September • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Rumble Shares Up 7% in Premarket After 27% Q2 Revenue Surge; More on Earnings • IH Market News • 08/13/2024 09:39:29 AM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results • GlobeNewswire Inc. • 08/12/2024 08:05:59 PM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences in August • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/22/2024 11:00:00 AM
- Perspective Therapeutics Announces Inclusion in the Russell 3000® Index • GlobeNewswire Inc. • 06/12/2024 11:00:00 AM
- Perspective Therapeutics Announces 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 06/11/2024 11:00:00 AM
- Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting • GlobeNewswire Inc. • 06/10/2024 08:10:00 PM
- Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 05/24/2024 12:01:41 PM
- Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 • GlobeNewswire Inc. • 05/20/2024 11:00:03 AM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM